Track market-moving stories before they get noisy

PALO ALTO, Calif.--(BUSINESS WIRE)--Global law firm Ropes & Gray selects Intapp DealCloud with Celeste to strengthen relationship management and bring agentic AI across the practice.

-

Newly launched restructuring-focused investment bank selects Intapp DealCloud to track relationships, manage deal pipeline, and scale with confidence

PALO ALTO, Calif.--(BUSINESS WIRE)--Intapp (NASDAQ: INTA), the governed AI platform for professional firms in highly regulated industries, announces that Ensis Partners, a growing investment bank, has selected Intapp DealCloud with Celeste to build its relationship and deal management foundation for its growing investment bank.

Building for the future

Ensis Partners is a New York City–based investment bank specializing in restructuring and bankruptcy advisory — a highly specialized segment of the investment banking landscape. Founded by seasoned industry veterans Richard Shinder and Mark Buschmann — who collectively bring decades of experience from firms including PJT Partners, Perella Weinberg, Blackstone, and Citigroup — Ensis launched in February 2026 with a clear vision: to create a firm purpose-built for the restructuring vertical.

From the outset, the firm’s founders recognized the importance of establishing a strong technology foundation before deals began to flow in earnest. Ensis Partners moved quickly to implement a platform capable of scaling with the firm, rather than waiting until data quality became a challenge.

As both founders had direct prior experience with DealCloud, including evaluating and deploying it at previous firms, Shinder and Buschmann didn’t need to evaluate competing CRM platforms. DealCloud's track record within their professional networks made it the clear choice.

"We knew from experience what good relationship and deal management infrastructure looks like, and we knew DealCloud was the right platform to build on,” said Shinder. “Starting with clean, structured data from day one means we're setting ourselves up for success as we grow, rather than trying to fix problems down the line."

Addressing relationship intelligence and deal management

Setting a foundation with AI in mind was a priority for the firm’s founders. Celeste, Intapp's agentic AI platform for financial and professional firms, is native to DealCloud — giving Ensis a single platform that structures its founders’ deep relationship networks and turns them into a competitive asset.

Ensis will use DealCloud to navigate the firm's restructuring business with full visibility into their relationship ecosystem, deal pipeline, associated fees and structures, and the complex constituent dynamics that define restructuring engagements. With AI that understands the firm's deal and relationship context, professionals can put that intelligence to work through natural conversation — surfacing insights on demand, automatically extracting key details from engagement documents, and keeping data current without manual data entry.

Partnering for success

To facilitate a smooth deployment of DealCloud, Ensis is working with Monarch, an Intapp partner that helps firms implement and derive long-term value from DealCloud. Monarch will leverage its proven implementation playbook and hands-on deployment approach to drive high-quality outcomes and long-term success for Ensis Partners' investment professionals.

"We're thrilled to be partnering with Ensis Partners at such an exciting stage of its journey,” said Brian Bissonette, Industry Principal, Investment Banking at Intapp. “The firm's founders bring exceptional experience and relationships in the restructuring space, and we look forward to helping them build an intelligent, scalable foundation — one that turns their relationships and deal activity into a real competitive advantage as the firm grows."

About Ensis Partners

Ensis Partners is a boutique, New York City–based investment banking and restructuring advisory firm founded by Richard Shinder and Mark Buschmann. The firm provides comprehensive restructuring and liability management advice relevant to complex capital structures and financial situations. With a focus on the upper-middle market, Ensis offers senior-level expertise across a range of transaction formats, including LMEs, special situations financings, Chapter 11 proceedings, and cross-border engagements. For more information, visit ensispartners.com.

About Intapp

Intapp (NASDAQ: INTA) is the governed AI platform for professional firms in highly regulated industries. Intapp's vertically tailored agentic solutions are built for the specialized workflows, complex relationship networks, and professional compliance requirements of accounting, consulting, investment banking, law, private capital, and real assets firms. By applying Firm AI to core processes and data, Intapp helps partners, dealmakers, and advisors drive firm growth, manage compliance, and improve profitability. Learn why the world's top firms trust Intapp's industry-specific enterprise solutions at intapp.com.

More News From Intapp, Inc.

Back to Newsroom

NORTH BETHESDA, Md.--(BUSINESS WIRE)---- $ESAB #ESAB--ESAB Corporation Announces Offering of Senior Notes.

Defender Capital LLC. acquired a new stake in ESAB Corporation (NYSE: ESAB) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 35,593 shares of the company's stock, valued at approximately $3,977,000. ESAB accounts for approximately 1.3% of Defender Capital LLC.'s holdings,

NORTH BETHESDA, Md.--(BUSINESS WIRE)---- $ESAB #ESAB--ESAB Corporation Announces CFO Transition.

Esab (ESAB - Free Report) shares rallied 8.8% in the last trading session to close at $102.95. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 12.2% loss over the past four weeks.

ESAB Corporation recently announced the appointment of R. Brent Jones as Chief Financial Officer, effective early May 2026. The company also expressed confidence in achieving the lower end of its core organic sales growth outlook, with multiple avenues to reach the upper end despite ongoing geopolitical uncertainty. 

ESAB also reaffirmed its previously issued 2026 guidance of core revenue between $2.85 billion and $2.95 billion, core adjusted EBITDA of $575 million to $595 million, and core adjusted EPS at $5.70-$5.90.

Shares of ESAB gained supported by a broader market rally following a U.S.-Iran ceasefire that eased industrial risk concerns. Expectations of post-war rebuilding and investment in the Middle East are seen as potential tailwinds for ESAB, which has a manufacturing presence in the region.

This maker of welding and cutting equipment is expected to post quarterly earnings of $1.37 per share in its upcoming report, which represents a year-over-year change of +9.6%. Revenues are expected to be $715.3 million, up 10.6% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Esab, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ESAB going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Esab is part of the Zacks Metal Products - Procurement and Fabrication industry. TriMas (TRS - Free Report) , another stock in the same industry, closed the last trading session 4.8% higher at $37.91. TRS has returned -5.1% in the past month.

TriMas' consensus EPS estimate for the upcoming report has changed -21.5% over the past month to $0.18. Compared to the company's year-ago EPS, this represents a change of -60.9%. TriMas currently boasts a Zacks Rank of #5 (Strong Sell).

The Zacks Metal Products - Procurement and Fabrication industry's prospects look bleak in the near term but ESAB and CENX seem poised to tide the challenges.

NORTH BETHESDA, Md.--(BUSINESS WIRE)---- $ESAB #ESAB1Q2026--ESAB Corporation Announces First Quarter 2026 Results.

ESAB Corporation (ESAB) Q1 2026 Earnings Call Transcript

MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By

Time Frame

Alert Type

Keywords

Page 1 of 324

Get 30 Days of MarketBeat All Access for Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.

Start Your 30-Day Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.

NORTH BETHESDA, Md.--(BUSINESS WIRE)---- $ESAB #ESAB--ESAB Corporation Completes Acquisition of Eddyfi Technologies.

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today announced that it has entered into a definitive agreement to acquire Onyx-Fire Protection Services Inc. (“Onyx-Fire”), an inspection-first provider of fire and life safety services in Canada, from funds managed by Blackstone Tactical Opportunities (“Blackstone”). The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions, including receipt of re.

APi (APG - Free Report) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +5.26%. A quarter ago, it was expected that this company would post earnings of $0.4 per share when it actually produced earnings of $0.44, delivering a surprise of +10%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

APi, which belongs to the Zacks Business - Services industry, posted revenues of $1.98 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 3.56%. This compares to year-ago revenues of $1.72 billion. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

APi shares have added about 27.2% since the beginning of the year versus the S&P 500's gain of 4.2%.

What's Next for APi?While APi has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for APi was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.44 on $2.16 billion in revenues for the coming quarter and $1.67 on $8.51 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Business - Services is currently in the bottom 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Willdan Group (WLDN - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 7.

This energy efficiency and sustainability consultant is expected to post quarterly earnings of $0.81 per share in its upcoming report, which represents a year-over-year change of +28.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Willdan Group's revenues are expected to be $89.55 million, up 4.9% from the year-ago quarter.

APi Group Corporation (APG) Q1 2026 Earnings Call Transcript

-

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) ("APi" or the "Company") today announced the pricing of the previously announced private offering by APi Group DE, Inc. ("APi DE"), a wholly owned subsidiary of the Company, of $500 million in aggregate principal amount of 5.75% senior notes due 2034 (the "Notes") at an offering price of 100% of the principal amount thereof. The Notes will be senior unsecured obligations of APi DE and will be fully and unconditionally guaranteed on a senior unsecured basis by the Company and certain of the Company's existing and future foreign and domestic subsidiaries. The offering is expected to close on or before May 14, 2026, subject to the satisfaction of customary closing conditions. APi intends to use the net proceeds from this financing for funding of the recently signed and announced Onyx-Fire Protection Services Inc. and Wtech Fire Group acquisitions, as well as for general corporate purposes.

The Notes are being offered in a private offering solely to parties reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and to non-U.S. persons in accordance with Regulation S under the Securities Act. No assurance can be given that the offering of the Notes will be completed, or, if completed, as to the terms on which it will be completed. This release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Forward Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements, and any such forward-looking statements are qualified in their entirety by reference to the following cautionary statements. All forward-looking statements speak only as of the date of this news release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements.

About APi:

APi is a global, market-leading business services provider of fire and life safety, security, elevator and escalator, and specialty services with a substantial recurring revenue base and over 500 locations worldwide. APi provides statutorily mandated and other contracted services to a strong base of long-standing customers across industries. APi has a winning leadership culture driven by entrepreneurial business leaders delivering innovative solutions for customers. More information can be found at www.apigroupinc.com.

More News From APi Group Corporation

Back to Newsroom

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today announced that its senior leadership team will be participating in a fireside chat during the William Blair 46th Annual Growth Stock Conference on Wednesday, June 3rd at 10:40 a.m. CT. A live webcast link and archived replay will be available in the “Events” area on the Investor Relations page of APi's website at APi Group Investor Relations - Events. Interested parties should check the Compan.

ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced that the Company presented its first dataset of alrizomadlin (APG-115), an MDM2-p53 inhibitor from the Company’s apoptosis-targeted pipeline, as monotherapy or in combination with lisaftoclax (APG-2575) in pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs), in a rapid oral presentation at the 62nd American Society of Clinical Oncology (ASCO) Annual Meeting.

The ASCO Annual Meeting showcases cutting-edge research in clinical oncology and advanced cancer therapies and is the world’s largest gathering of the clinical oncology community. This year marks Ascentage Pharma’s ninth consecutive appearance at ASCO. A total of six studies involving three of the Company’s key assets were selected for presentation, including three rapid oral presentations.

The data presented demonstrated preliminary antitumor activity and a manageable tolerability profile of alrizomadlin in pediatric solid tumors. Results showed that alrizomadlin monotherapy demonstrated initial clinical benefit in pediatric rhabdomyosarcoma (RMS), with one pediatric patient achieving a complete response (CR). In combination with investigational selective Bcl-2 inhibitor lisaftoclax, encouraging antitumor activity was observed, with an objective response rate (ORR) of 23.5% among 17 response-evaluable patients, including one complete response in a patient with Ewing sarcoma and three partial responses (PRs). In terms of safety, alrizomadlin, either as monotherapy or in combination with lisaftoclax, demonstrated a manageable safety profile in pediatric patients with solid tumors.

Alrizomadlin is an orally administered, highly selective MDM2-p53 inhibitor independently developed by Ascentage Pharma. It is the first investigational agent of its class to enter clinical development in China and has global first-in-class potential. By blocking the MDM2-p53 protein-protein interaction, alrizomadlin restores the tumor suppressor activity of p53 and induces apoptosis in tumor cells. Recently, alrizomadlin was officially included by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) in the Pilot Program for the Support of Anti-tumor Drugs R&D for Kids, also known as the “SPARK Plan,” for development in pediatric solid tumors including neuroblastoma, rhabdomyosarcoma, and Ewing sarcoma.

Professor Yizhuo Zhang, principal investigator of the study from the Department of Pediatric Oncology at Sun Yat-sen University Cancer Center, said: “Relapsed/refractory pediatric sarcomas are associated with extremely poor prognosis and substantial unmet medical needs. The data presented at the ASCO meeting demonstrated a favorable tolerability profile and promising anti-tumor effect for alrizomadlin both as monotherapy and in combination with lisaftoclax, with the complete response (CR) cases being particularly encouraging. As a key candidate included in the SPARK Plan, alrizomadlin has the potential to become a first-in-class therapy, address unmet medical needs, and bring new hope for long-term survival to pediatric patients.”

Professor Yi Zhang, investigator of the study from the Department of Pediatrics at Beijing Tongren Hospital, Capital Medical University, said: “Treatment options for pediatric solid tumors, especially advanced soft-tissue sarcomas, remain very limited. The clinical data generated by the alrizomadlin combination regimen are therefore particularly meaningful. This apoptosis pathway-targeting therapy demonstrated favorable tolerability and encouraging objective response rates, further supporting the therapeutic potential of dual-target combination approaches in refractory pediatric tumors and providing valuable direction for future precision drug development in pediatric oncology.”

Yifan Zhai, MD, Chief Medical Officer of Ascentage Pharma, said: “Pediatric solid tumors continue to represent an area of significant unmet medical need. The data presented at ASCO mark our first presentation of alrizomadlin clinical data in pediatric solid tumor patients and demonstrated encouraging preliminary clinical benefit and tolerability. Importantly, alrizomadlin has already been included by the CDE in the SPARK Plan for potential development in multiple pediatric solid tumors. The data presented provide initial clinical evidence supporting this development strategy. We will continue to advance the related clinical studies with the goal of bringing new treatment options to pediatric patients in urgent need.”

Key highlights from the study presented at the 2026 ASCO Annual Meeting are as follows:

Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)
Abstract #: 10012
Presentation Type: Rapid Oral Presentation
Session Title: Pediatric Oncology II
First Author: Yizhuo Zhang, MD, Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
Key Highlights:

Research Background: This multicenter clinical trial conducted in China evaluated the safety and preliminary efficacy of alrizomadlin (APG-115) as monotherapy or in combination with lisaftoclax in heavily pretreated pediatric patients with relapsed/metastatic RMS, Ewing sarcoma (EWS), neuroblastoma (NB), and other solid tumors.Efficacy Data: In the monotherapy arm, 1 patient with refractory RMS achieved CR. In the combination arm, among 17 response-evaluable pediatric patients with relapsed/refractory solid tumors, the ORR was 23.5%, including 1 CR in a patient with EWS, as well as PRs in 2 patients with RMS and 1 patient with NB. The disease control rate (DCR) was 70.6%.Safety Data: No dose-limiting toxicities (DLTs) were observed in either the monotherapy or combination arm. Adverse events were primarily gastrointestinal and hematologic, with few serious adverse events and no treatment-related deaths or discontinuations.Conclusion: The regimen demonstrated a manageable safety profile and preliminary antitumor activity in pediatric solid tumors, supporting further investigation. * Alrizomadlin is currently under investigation and has not yet been approved by the US FDA.

About Ascentage Pharma

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.

The Company’s first approved product, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA- and EMA-cleared registrational Phase III trial, called POLARIS-2, of olverembatinib for CML, as well as an FDA- and EMA-cleared registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.

The Company’s second approved product, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA- and EMA- cleared GLORA study of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA- and EMA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 29, 2026, the sections headed “Forward-looking Statements” and “Risks Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited where the Company’s ordinary shares are listed it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information
Investor Relations:
Stella Yang
Ascentage Pharma
[email protected] 
+1 (301) 792-6286

Stephanie Carrington
ICR Healthcare
[email protected]
+1 (646) 277-1282

Media Relations:
Sean Leous
ICR Healthcare
[email protected]
+1 (646) 866-4012

APi Group Corporation (APG) Presents at 46th Annual William Blair Growth Stock Conference Transcript

APi Group Corporation (NYSE: APG) (“APi” or the “Company”), a global, market-leading business services provider of safety and specialty services, today

On June 11, 2026, APi Group Corp (APG) shares rose 3.1% today, bringing the current price to $42.66. The stock has experienced a 52-week range of $31.75 to $49.

Carpenter Technology has delivered exceptional YTD and multi-year returns, driven by strong margin expansion and aerospace & defense demand. CRS guides for FY2024 operating income of $700–$705 million (+33% y/y) and $350 million in adjusted FCF, with continued growth expected into 2027. Despite robust fundamentals and margin gains, CRS trades at a low FCF yield (~1.6%), making shares unattractive for new entrants at current valuations.

SAN DIEGO--(BUSINESS WIRE)--Aspera Biomedicines launches second ADAR1p150 crystallization experiment to the ISS aboard SpaceX CRS-34, advancing oral Rebecsinib for 20+ cancers.

Carpenter Technology’s alloys are used in engines and elsewhere. The stock is a buy. (Getty Images)

Dental implants. Cellphones. Golf clubs. Boeing planes. No, these aren’t clues frustrating fans of the popular Connections puzzle. They are, nonetheless, connected: Each one began in the heat of Carpenter Technology’s high-tech furnaces.

Investors interested in Basic Materials stocks should always be looking to find the best-performing companies in the group. Is Carpenter Technology (CRS - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Basic Materials peers, we might be able to answer that question.

Carpenter Technology is a member of the Basic Materials sector. This group includes 248 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Carpenter Technology is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for CRS' full-year earnings has moved 2% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

Based on the most recent data, CRS has returned 39.2% so far this year. Meanwhile, the Basic Materials sector has returned an average of 13.6% on a year-to-date basis. This shows that Carpenter Technology is outperforming its peers so far this year.

Another Basic Materials stock, which has outperformed the sector so far this year, is Lithium Americas Corp. (LAC - Free Report) . The stock has returned 14.5% year-to-date.

For Lithium Americas Corp., the consensus EPS estimate for the current year has increased 65.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).

To break things down more, Carpenter Technology belongs to the Steel - Speciality industry, a group that includes 6 individual companies and currently sits at #163 in the Zacks Industry Rank. Stocks in this group have gained about 33.8% so far this year, so CRS is performing better this group in terms of year-to-date returns.

On the other hand, Lithium Americas Corp. belongs to the Mining - Miscellaneous industry. This 72-stock industry is currently ranked #154. The industry has moved +24.1% year to date.

Carpenter Technology and Lithium Americas Corp. could continue their solid performance, so investors interested in Basic Materials stocks should continue to pay close attention to these stocks.

SpaceX is expected to make its Nasdaq debut on June 12 in what could become the largest initial public offering in history.

The company is targeting a valuation of about $1.8 trillion, with the proposed ticker SPCX and an unusually large retail allocation.

That alone would be enough to stir a market frenzy. But some investors are already looking one step away from the listing itself.

Rather than chase SpaceX directly, they are buying publicly traded suppliers tied to its rockets, satellites and Starlink terminals.

SpaceX has become the dominant force in the US launch market as it accounted for about 87% of US space launches in 2025 and completed 170 orbital launches, or nearly one every other day.

That dominance is what makes the supplier trade interesting.

SpaceX is famous for building much of its technology in-house, partly because it struggled to source parts in its early years.

As a result, the outside suppliers it does use can look especially valuable.

They are not casual vendors, but part of a carefully controlled supply chain supporting rockets, satellites and ground equipment.

The idea is an old one. During a gold rush, the companies selling picks, shovels and denim can sometimes do better than the miners.

In this case, the “picks and shovels” are extreme-temperature metals, specialty alloys and chips used across the SpaceX ecosystem.

Analysts are now pointing to three names that have caught the market’s attention: Materion, Carpenter Technology and STMicroelectronics.

Also read: SpaceX vs OpenAI: Which IPO could deliver bigger returns?

Materion has been one of the most dramatic movers. The Ohio-based advanced-materials company supplies niobium metal and other specialty materials used in extreme-temperature environments, according to TheStreet Pro analyst Ed Ponsi.

That makes it relevant to rocket-engine applications, where heat resistance is critical. Materion’s market value remains below $5 billion, giving it a smaller base than many aerospace suppliers.

Ponsi noted that the stock has gained about 180% over the past 12 months and projected a technical target of $275.

Carpenter Technology offers a different kind of exposure. The Philadelphia company has been around for 135 years and has roots in the US space programme dating back to Apollo.

Today, it supplies high-performance specialty metals used in Starship and other spacecraft. Its shares have gained about 93% over the past year and recently touched all-time highs.

Ponsi placed a $525 technical target on the stock, while disclosing that he is personally long Carpenter shares.

STMicroelectronics, listed in the US as STM, is the chip play.

The Geneva-based semiconductor group has supplied SpaceX for about a decade, including radio-frequency antenna chips, microcontrollers and secure elements used in Starlink terminals. It is also the sharpest momentum trade of the three, with shares up about 147% this year, according to Ponsi.

But there is a caveat as its relative strength index has flashed overbought for four straight weeks, and Ponsi suggested a more attractive entry could come on a pullback toward $56.50.